Abstract: The invention relates to a new protein hydrogel created on the basis of low-concentrated components: reagents A and B, the method of hydrogel preparation and its use.

Abstract: The present invention relates to a method of preparation of Glycolipid carboxylic acids of Formula I by selective hydrolysis of corresponding esters by enzymes. The method provides preparation of compounds of Formula I in high yield by an environmentally benign, robust, economical, simple and convenient method.

Abstract: The invention is in the field of vaccines and relates to oligomers having a selected degree of polymerization, obtained by connecting together a number of carbocyclic repeating units, and to conjugated derivatives thereof. The oligomers and conjugated derivatives thereof of the invention also have a selected degree of acetylation. The derivatives of the invention are useful for the preparation of immunogenic compositions, e.g. in the form of a vaccine.

Abstract: Provided herein are compositions, devices, systems and methods for DNA oligomer synthesis. Further provided are devices comprising addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.). The compositions, devices, systems and methods described herein provide improved synthesis, storage, density, and retrieval of biomolecule-based information.

Abstract: Provided is a method for collecting RNA contained in skin surface lipids (SSL). A method for preparing SSL-derived RNA. In this method, an aqueous solution containing RNA prepared from SSL of a subject is mixed with a water-soluble organic solvent, and the resulting mixture is allowed to contact with a solid phase material to separate RNA. By adjusting the concentration of the water-soluble organic solvent in the mixture, the yield of RNA improves.

Abstract: The present disclosure relates to compounds that inhibit SETBP1 or XP01 activities. Also disclosed are methods of using such compounds to increase the expression of embryonic and fetal hemoglobin molecules, and to treat sickle cell disease and ?-thalassemia. The present invention relates to unexpected findings that transcription factor SETBP1 regulates embryonic and fetal hemoglobin repression, and inhibition of SETBP1 can induce the expression of embryonic and fetal hemoglobins.

Abstract: Disclosed herein are methods for preparing compositions containing oligonucleotides. Methods of this disclosure involve subjecting an aqueous solution of a oligonucleotide to ultrafiltration/diafiltration (UF/DF) in order to form a retentate containing the oligonucleotide, where the ultrafiltration/diafiltration (UF/DF) is carried out using an aqueous buffer solution containing one or more salts. Also disclosed herein are oligonucleotide-containing compositions obtained by these methods.

Abstract: Disclosed are methods, genetically engineered cells, sialyltransferases and nucleic acid molecules encoding said sialyltransferases for producing sialylated oligosaccharides as well as the use of said sialylated oligosaccharides for providing nutritional compositions.

Abstract: Ester and sulfated derivatives of hyaluronic acid are described for use in the prevention and treatment of the initial stage of SARS-CoV-2 disease.

Abstract: Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.

Abstract: The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.

Abstract: The present disclosure belongs to the field for preparation of chitosan oligosaccharide, and particularly relates to a chitosan oligosaccharide sulfate and a preparation method thereof. The method is as follows: adding an equal volume of 1.0%-2.0% by mass of potassium sulfate solution into 2.0%-4.0% by mass of chitosan oligosaccharide hydrochloride solution and evenly mixing to obtain a mixed solution, allowing a molar ratio of amino to sulfate ions in the mixed solution to be 2:1, then adding absolute ethyl alcohol to obtain a chitosan oligosaccharide sulfate suspension, standing, filtering, collecting precipitates, washing, drying and smashing to finally obtain the chitosan oligosaccharide sulfate.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment of sepsis and hypercytokinemia.

Abstract: The present invention relates to a lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids and a method for isolating and/or purifying nucleic acids.

Abstract: Provided herein are compounds, compositions, and methods for rapid isolation of nucleic acids from a sample.

Abstract: Disclosed is a method for preparing cellulose and lignin oil by depolymerizing lignocellulose without exogenous hydrogen, including: performing reaction on the lignocellulose dispersed into an aqueous medium at 120° C. to 180° C. under the action of a catalyst; and separating a reaction product to obtain the cellulose and the lignin oil. The catalyst includes a carrier and an active ingredient loaded on the carrier, where the active ingredient is selected from one of platinum, palladium, ruthenium and nickel; the carrier is selected from one of a metal oxide, a metal composite material, silicon dioxide, nitrogen-doped carbon, molybdenum carbide and molybdenum nitride; and the metal oxide is selected from one of niobium oxide, tantalum oxide, tungsten oxide, zirconium oxide, aluminum oxide, titanium dioxide and molybdenum oxide.

Abstract: The present invention relates to the compound of formula (1a) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: Provided is DHA, or a composition comprising DHA, for use in treatment of a biofilm in a subject and for use in treatment of a disease or infection associated or caused by a biofilm in a subject.

Abstract: 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Abstract: This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.